Thus, different studies suggest the use of serum adiponectin levels as a diagnostic measure of the necro-inflammatory grade and fibrosis in NAFLD, as well as it being a potential NAFLD therapeutic target [115]. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.